Both univariate and multivariate survival analysis indicated poorer survival in patients with low TRIM14 expression, supporting our observation that TRIM14 downregulation promotes NSCLC progression, which may lead to a poor clinical outcome in patients. Here, TRIM14 is linked to non-small cell lung carcinoma.